Merav Bassan - 11 Dec 2023 Form 4 Insider Report for BiomX Inc. (PHGE)

Role
Chief Development Officer
Signature
/s/ Merav Bassan
Issuer symbol
PHGE
Transactions as of
11 Dec 2023
Net transactions value
$0
Form type
4
Filing time
13 Dec 2023, 16:43:55 UTC
Previous filing
31 Oct 2023
Next filing
15 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer -47,500 -100% 0 11 Dec 2023 Common Stock 47,500 $7.02 Direct F1, F2
transaction PHGE Common Stock Options - Right to Buy Award +12,500 12,500 11 Dec 2023 Common Stock 12,500 $0.2749 Direct F1, F2
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer -100,000 -100% 0 11 Dec 2023 Common Stock 100,000 $1.41 Direct F3, F4
transaction PHGE Common Stock Options - Right to Buy Award +71,429 71,429 11 Dec 2023 Common Stock 71,429 $0.2749 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 47,500 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 12,500 shares, having an exercise price of $0.2749 per share.
F2 The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
F3 On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 100,000 shares of the Issuer's common stock granted to the Reporting Person on March 29, 2022. In exchange, the Reporting Person received a replacement option, for 71,429 shares, having an exercise price of $0.2749 per share.
F4 The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 29, 2023, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.